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Nitric oxide (NO) plays an important role in synaptic plasticity as a retrograde messenger at glutamatergic synapses. Here we describe
that, in hippocampal pyramidal cells, neuronal nitric oxide synthase (nNOS) is also associated with the postsynaptic active zones of
GABAergic symmetrical synapses terminating on their somata, dendrites, and axon initial segments in both mice and rats. The NO
receptor nitric oxide-sensitive guanylyl cyclase (NOsGC) is present in the brain in two functional subunit compositions:11 and21.
The 1 subunit is expressed in both pyramidal cells and interneurons in the hippocampus. Using immunohistochemistry and in situ
hybridizationmethods,wedescribe that the1 subunit isdetectableonly in interneurons,whicharealwayspositive for1 subunit aswell;
however, pyramidal cells are labeled only for 1 and 2 subunits. With double-immunofluorescent staining, we also found that most
cholecystokinin- and parvalbumin-positive and smaller proportion of the somatostatin- and nNOS-positive interneurons are1 subunit
positive.We also found that the1 subunit is present in parvalbumin- and cholecystokinin-positive interneuron terminals that establish
synapses on somata, dendrites, or axon initial segments. Our results demonstrate that NOsGC, composed of11 subunits, is selectively
expressed in different types of interneurons and is present in their presynaptic GABAergic terminals, in which it may serve as a receptor
for NO produced postsynaptically by nNOS in the very same synapse.
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Introduction
Nitric oxide (NO) participates in the molecular machinery of
several forms of synaptic plasticity, including long-term potenti-
ation (LTP) and long-term depression, whereby it may influence
learning and memory processes (Garthwaite and Boulton, 1995;
Daniel et al., 1998; Prast and Philippu, 2001; Koylu et al., 2005;
Edwards and Rickard, 2007). The neuronal substrates of these
processes are the networks of hippocampal pyramidal cells regu-
lated by several different interneuron classes (Freund and
Buzsaki, 1996). NO action in the brain is generally linked to
retrograde signaling at glutamatergic synapses, in which NO is
postsynaptically released and regulates presynaptic release. NO is
generated from arginine by nitric oxide synthases (NOS-I, NOS-
II, and NOS-III) (Forstermann et al., 1991; Moncada et al., 1991;
Bredt and Snyder, 1992). The calcium-dependent neuronal NOS
(nNOS or NOS-I) is expressed in both a subpopulation of hip-
pocampal interneurons (Jinno and Kosaka, 2002, 2004) and py-
ramidal cells (Wendland et al., 1994; Blackshaw et al., 2003), in
which it can contribute to LTP (Doyle et al., 1996; Hawkins et al.,
1998; Zorumski and Izumi, 1998; Bon and Garthwaite, 2003).
nNOS binds to PDZ [Postsynaptic density-95 (PSD-95)/Discs
large/Zona occludens-1]-domain-containing scaffold proteins in
excitatory postsynaptic densities (Christopherson et al., 1999;
Tochio et al., 2000).
NO induces cGMP production, which is a second-messenger
molecule that exerts its effects through ion channels, protein ki-
nases, and phosphodiesterases. cGMP also contributes to hip-
pocampal synaptic plasticity (Zhuo et al., 1994; Arancio et al.,
2001; Monfort et al., 2002). Only one of the two types of cGMP-
forming enzymes is sensitive to NO, and this NO-sensitive gua-
nylyl cyclase (NOsGC) is thought to be the principal NO receptor
(Hobbs, 1997; Russwurm and Koesling, 2002; Koesling et al.,
2004). In addition, in hippocampal neurons, cGMP seems to be
generated only by NOsGC (Kobialka and Gorczyca, 2000;
Teunissen et al., 2001; Schulz, 2005). The two functionally rele-
vant subunit compositions in the hippocampus are 11 and
21. The distribution of NOsGC 1 subunit and its mRNA has
been reported previously (Gibb and Garthwaite, 2001; Burette et
al., 2002; Ding et al., 2004; Pifarre et al., 2007), and it was shown
to be localized in pyramidal cells and in some interneurons. In
addition,  and  subunits were found to colocalize in the same
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cells (Ding et al., 2004), but the1- and2-containing complexes
were not distinguished. At the subcellular level, NOsGC is pri-
marily localized to the presynaptic active zone of excitatory ter-
minals (Burette et al., 2002).
Here we show that nNOS is associated with the postsynaptic
specialization of GABAergic synapse terminating on hippocam-
pal pyramidal cell somata, dendrites, and axon initial segments
(AISs), and NOsGC is distributed in the presynaptic GABAergic
terminals in both mice and rats. In addition, we revealed that
NOsGC 11 is located only in interneurons, whereas 2-
containing complexes are detectable only in pyramidal cells in
mice and rats. Our results suggest that the GABAergic input of
pyramidal cells can be retrogradely modulated through a so far
unexplored nNOS–NOsGC pathway in the hippocampus, which
uses a molecular composition of NO receptor distinct from that
operating at glutamatergic pathways.
Materials andMethods
Animals. Sixteen adult male Wistar rats and eight adult male C57BL/6
mice (Charles River, Budapest, Hungary) in addition to two male nNOS
knockout (KO) mice (Jax mice; The Jackson Laboratory, Bar Harbor,
ME) were anesthetized with an intraperitoneal injection of an anesthetic
mixture (containing 2.5% ketamine, 0.5% xilazin-hydrochloride, 0.25%
promethazinium-chloride, 0.0025%benzetonium-chloride, and 0.002%
hydrochinonum) used at 0.2 ml/100 g body weight. First, animals were
perfused through the heart with 0.9% NaCl solution followed by a fixa-
tive. These perfusions were performed differently depending on the type
of immunohistochemistry or in situ hybridization that followed. In the
preembedding immunogold experiments (showing synaptic nNOS gold
labeling), three rats, three mice and two nNOS KO mice were perfused
through the heart with a fixative containing 1% paraformaldehyde in 0.1
M phosphate buffer (PB) (pH 7.4) for 60 min. In the preembedding
immunoperoxidase experiments (colocalizing NOsGC 1 and 1 sub-
units) and in the in situ hybridization experiments, seven rats and two
mice were perfused with a fixative containing 4% paraformaldehyde in
0.1 M PB for 30 min. Similar fixative perfusion was used for three rats in
the immunofluorescence experiments. All solutions used for perfusions
in the in situ hybridization experiments were first treated with 0.1%
diethylpyrocarbonate (DEPC) for 1 h and then autoclaved. In the preem-
bedding immunoperoxidase experiments [localizing NOsGC 1 sub-
units at the electron microscopic (EM) level], three rats and three mice
were perfused first for 2 min with a fixative containing 4% paraformal-
dehyde in Na-acetate buffer, pH 6.0, and then with a fixative containing
4% paraformaldehyde in Borax buffer, pH 8.5, for 40 min. All fixative
perfusions were followed by perfusionwith 0.1 M PB for 10min, and then
the brains were removed from the skull and were not postfixed. Blocks
from the dorsal hippocampiwere dissected and sectioned on a vibratome
at 60 m thickness for immunogold and immunoperoxidase experi-
ments, at 50m thickness for in situ hybridization, and in the case of the
fluorescent experiments at 40mthickness, followed bywashing in 0.1 M
PB. Then they were incubated in 10 and 30% sucrose for cryoprotection
and freeze thawed over liquid nitrogen several times. After repeated
washes in 0.1 M PB, the sections were processed for immunostaining.
Experimentswere performed in accordancewith the Institutional Ethical
Codex and the Hungarian Act of Animal Care and Experimentation
guidelines, which are in concert with the European Communities Coun-
cil Directive of November 24, 1986 (86/609/EEC).
Preembedding immunoperoxidase staining. Incubation of sections in
1% human serum albumin (HSA) (Sigma, St. Louis, MO) diluted in
Tris-buffered saline (TBS) was followed by a 48 h incubation in solutions
of primary antibodies raised against NOsGC 1 subunit (rabbit poly-
clonal antibody; catalog number G4280, lot number 011K4888; 1:10,000
for the mirror experiments, 1:1000 for EM measurements; Sigma) and
NOsGC1 subunit (rabbit polyclonal antibody; catalog number 160897,
lot number 134521, 1:4000; Cayman Chemical, Ann Arbor, MI) diluted
in TBS. After subsequent extensive washing in TBS, the sections were
incubated with biotinylated anti-rabbit (goat polyclonal antibody, 1:200;
Vector Laboratories, Burlington, CA), followed by avidin–biotinylated
horseradish peroxidase complex (Elite ABC, 1:300; Vector Laboratories)
diluted in TBS for 3 h. The immunoperoxidase reaction was developed
using 3,3-diaminobenzidine (DAB) (Sigma) as a chromogen. In themir-
ror experiments, the DABwas intensified with ammonium nickel sulfate
(DAB-Ni) in three rats. In the case of the fourth rat, after incubation in
ABC and subsequent washes in TBS, sections were incubated in biotinyl
tyramide solution (1:50, Renaissance TSA kit; PerkinElmer Life Sciences,
Boston, MA) diluted in its own buffer for 15 min, followed by washes in
TBS and a second incubation in ABC, again followed by DAB-Ni devel-
opment. The sections were treated with osmium tetroxide in PB on ice.
Sections in mirror experiments were not osmicated. After that, sections
were dehydrated in ascending alcohol series and propylene oxide and
embedded in Durcupan (ACM; Fluka, Buchs, Switzerland). During de-
hydration, the sections were treated with 1% uranyl acetate in 70% eth-
anol for 30 min.
Preembedding immunogold and combined immunogold–immunoper-
oxidase staining.To localize nNOS, first we incubated sections in 1%HSA
and then in the solution of primary antibody for nNOS (rabbit poly-
clonal antibody, 1:500; Zymed Laboratories, San Francisco, CA) or in the
combined staining experiments in mixtures of primary antibodies for
either nNOS and cholecystokinin (CCK) (mouse monoclonal antibody,
1:5000; CURE Digestive Diseases Research Center, Los Angeles, CA) or
nNOS and parvalbumin (PV) (mouse monoclonal antibody, 1:7000;
Swant, Bellinzona, Switzerland) diluted in TBS for 48 h. After repeated
washes in TBS, sections were treated with blocking solution (Gel-BS)
containing 0.5% cold water fish skin gelatin (GE Healthcare, Little Chal-
font, UK) and 0.5%HSA in TBS for 1 h. This was followed by incubation
with either 1 nm gold-conjugated anti-rabbit (goat polyclonal antibody,
1:80; GE Healthcare) or 0.8 nm gold-conjugated anti-rabbit (goat poly-
clonal antibody, 1:80; Aurion,Wageningem, TheNetherlands) diluted in
Gel-BS for 24 h. After intensive washes in TBS, the sections were treated
with 2% glutaraldehyde in PB for 15min to fix the gold particles into the
tissue. This was followed by washes in PB and in enhancement condi-
tioning solution (ECS; Aurion). After this the sections were incubated in
silver enhancement solution (SE-EM; Aurion) for 60 min at room tem-
perature. This was followed by wash in ECS and repeated washes in PB.
Then sections of single immunogold reactions were processed for osmi-
cation and dehydration as described below. The sections of the combined
method were incubated with biotinylated anti-mouse (horse polyclonal
antibody, 1:200; Vector Laboratories) for 24 h, followed by incubation in
Elite ABC (1:300; Vector Laboratories) diluted in TBS for 3 h. The im-
munoperoxidase reaction was developed using DAB as chromogen. The
sections were treated with osmium tetroxide in PB on ice. After this,
sectionswere dehydrated in ascending alcohol series andpropylene oxide
and embedded in Durcupan. During dehydration, the sections were
treated with 1% uranyl acetate in 70% ethanol for 30 min. For the elec-
tron microscopic investigations, small resin embedded tissue samples
were cut from the sections and glued onto plastic blocks. After this, 70-
and 80-nm-thick sections were prepared using a Leica (Nussloch, Ger-
many) EM UC6 ultramicrotome and picked up on single-slot copper
grids. The sections were examined using a Hitachi (Tokyo, Japan)
H-7100 electron microscope.
Double-immunofluorescent staining. Incubation of sections in 1% hu-
man serum albumin was followed by a 2 d incubation in mixtures of
primary antibodies for either NOsGC 1 subunit (1:1000) together with
CCK (1:3000), PV (1:1000), nNOS (mouse monoclonal anti-nNOS,
N2280, 1:500; Sigma), or somatostatin (SOM) (MAB354, 1:70; Chemi-
con, Temecula, CA) or for nNOS together with cannabinoid CB1 recep-
tor (rabbit polyclonal antibody, 1:500) (Hajos et al., 2000) or substance P
receptor (SPR) (AB5060, 1:5000; Chemicon). The primary antibodies
were diluted in TBS. After repeated washes in TBS, the sections were
incubated in mixtures of fluorescent-labeled secondary antibodies for
5 h. To detect CCK, PV, or nNOS, we used red fluorescent Alexa 594
anti-mouse IgG (1:200; Invitrogen, Carlsbad, CA). For CB1 and SPR, we
used green fluorescent Alexa 488 anti-rabbit IgG (1:200; Invitrogen). For
SOM, we used FITC-conjugated anti-rat IgG (1:50; Jackson ImmunoRe-
search,WestGrove, PA). To detect theNOsGC1 subunit antibodies, we
used either green fluorescent Alexa 488 anti-rabbit IgG or red fluorescent
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Alexa 594 anti-rabbit IgG (1:200; Invitrogen). We did not use any deter-
gent during the immunostaining. The sections were treated with 0.025%
CuSO4 solution for 30 min to reduce autofluorescence (Schnell et al.,
1999) and then were washed in TBS, transferred onto microscope slides,
and covered with Vectashield (Vector Laboratories). The sections were
evaluated using a Zeiss (Oberkochen, Germany) Axioplan2 microscope.
Controls. Primary antibodies were tested by the laboratories of origin
(see references above), andwe also found the expected labeling pattern in
cortex and hippocampus.We found no specific staining pattern with the
nNOS antibodies in nNOSKOmice (see Fig. 1). NOsGC antibodies were
tested further in this work (see below). Secondary antibodies were exten-
sively tested for possible cross-reactivity with the other secondary or
primary antibodies, and possible tissue labeling without primary anti-
bodies was also tested to exclude autofluorescence or specific back-
ground labeling by the secondary antibodies. No specific staining was
observed under these control conditions.
Synthesis of riboprobes for NOsGC 1 and 2 subunits. Primarily non-
overlapping segments (identity ratio 50%) of the rat NOsGC 1 and
NOsGC 2 coding sequences (GenBank accession numbers gi:1655846
and gi:13027399 for NOsGC 1 and NOsGC 2, respectively) were am-
plified by reverse transcription-PCR from cDNAderived fromWistar rat
hippocampal total mRNA sample. The length and the sequence of prim-
ers are listed below for both probes; numbering of the nucleotide posi-
tions starts from the beginning of the open reading frame: NOsGC 1
probe, 800 bp from 481 to 1280 (forward primer, 5-CTC AAG ATC
ACG GGG GAG T; reverse primer, 5-ACT AGC GAG GAC TGG GGT
TT); NOsGC 2 probe, 903 bp from 444 to 1346 (forward primer, 5-
CGA GTC CTT CAG CTC TCT GG; reverse primer, 5-TGG GAA GTA
CCT TGT GGA ATG). The primers were designed using the Primer3
software (Rozen and Skaletsky, 2000). PCR products were cloned into
the SmaI site of pBluescript II SK (Fermentas, Vilnius, Lithuania). The
integrity and orientation of clones were verified by sequencing. NOsGC
1 probe was linearized by XbaI and PstI digestion for the antisense and
sense probe, respectively. NOsGC 2 was linearized byNotI andHindIII
digestion for the antisense and sense probe, respectively. The linearized
template DNA was gel extracted, precipitated, resuspended in DEPC-
treated H2O at a concentration of 1 g/l, and stored at20°C. In vitro
transcription was performed for 2 h at 37°C in a total volume of 20 l
containing 1 g of template DNA, 1 transcription buffer, 1 Digoxi-
genin RNA LabelingMixture, 40 U of RNase inhibitor, and 20 U of T3 or
T7 RNA polymerase, which was adjusted to 20 l using DEPC-free
double-distilled H2O. All components were from Roche Molecular Di-
agnostics (Mannheim, Germany). Digoxigenin-labeled riboprobes were
DNase-treated and purified using the RNeasy MinElute Cleanup kit
(Qiagen, Hilden, Germany). Finally, the integrity and quantity of the
riboprobes were determined using gel electrophoresis.
In situ hybridization. All solutions used for in situ hybridization were
first treated with 0.1% DEPC for 1 h and then autoclaved. Chemicals
were purchased from Sigma (Budapest, Hungary), if otherwise not indi-
cated. Incubation of the 50-m-thick rat or mouse brain slices was per-
formed in a free-floatingmanner inRNase-free sterile culturewells for all
steps. First the sectionswerewashed in phosphate-buffered saline (PBST,
inmM: 137NaCl, 2.7 KCl, 10Na2HPO4, 2 KH2PO4, and 0.1%Tween 20,
pH 7.4) three times for 20 min. Hybridization was then performed over-
night at 60°C in 0.6 ml of hybridization buffer containing the
digoxigenin-labeled riboprobe (1.2 g/ml). Hybridization buffer con-
sisted of 50% formamide, 5 SSC, 1%SDS, 50g/ml yeast tRNA, and 50
g/ml heparin in DEPC-treated H2O. During the overnight incubation
and the after three washing steps, the sections were continuously incu-
bated on a shakerwithin a humid chamber. After incubation, the sections
were first washed for 30 min at 60°C in wash solution 1 (containing 50%
formamide, 5 SSC, and 1% SDS in DEPC-treated H2O) and then twice
for 45 min at 60°C in wash solution 2 (containing 50% formamide and
2 SSC in DEPC-treated H2O). The section were next washed for 5 min
in 0.05 MTris-buffered saline containing 0.1%Tween 20 (TBST), pH 7.6,
and then blocked in TBST containing 10% normal goat serum (TBSTN)
for 1 h, both at room temperature. Next, sections were incubated over-
night at 4°C with sheep anti-digoxigenin Fab fragment conjugated to
alkaline phosphatase (RocheMolecular Diagnostics) diluted at 1:1000 in
TBSTN. The next day, the sections were washed three times for 20min in
TBST and then developedwith freshly prepared chromogen solution in a
total volume of 10ml, containing 3.5l of 5-bromo-4-chloro-3-indolyl-
phosphate and 3.5 l of nitro blue tetrazolium chloride dissolved in
chromogen buffer (in mM: 100 NaCl, 100 Tris-Cl, pH 9.5; 20 MgCl2, 2
()tetramisole hydrochloride, and 0.1% Tween 20). The sections were
gently rinsed in 1ml of the above developing solution in the dark for 6–8
h, and the reaction was stopped using PBST. Finally, the sections were
washed in 0.1 M PB three times for 10 min and mounted in Vectashield
(Vector Laboratories) onto glass slides.
Data analyses and statistics. In the fluorescent experiments, in each of
the three rats, six 40-m-thick coronal sections were tested per colocal-
ization in a systematic random manner from the rostral, medial, and
caudal parts of the rostrocaudal extent of the rat dorsal hippocampus.
Colocalization of antigens was investigated only when the nucleus of a
cell could be detected to ensure that a large part of the cell was tested.We
measured the cross-sectional area of all examined cells. Cells were sam-
pled with the help of a grid placed over the photos of each section in a
systematic randommanner. Once the cells were selected, they were scru-
tinized individually. We used NIH ImageJ image analyzer software for
measuring the cells and StatSoft (Tulsa, OK) Statistica software (version
7) for data analysis. We did not intend to define the absolute number of
the examined cells in the hippocampus but performed a quantitative
measurement of the ratios using Abercrombie’s correction (Abercrom-
bie, 1946).
In the immunogold experiments, after extensive testing and adjusting
of reaction conditions, final measurements of gold particles were per-
formed from serial sections from each animal, in which background
labeling was minimal. Immunoparticles for nNOS were counted within
the anatomically defined synaptic junctions and under other cell mem-
brane segments adjacent to synapses, without synaptic junctions. Gold
particles were considered to be associated with the cell membrane only
when they were not farther away from the membrane than 40 nm.
Because most data populations in this work did not have a Gaussian
distribution according to the Shapiro–Wilk’s W test, we used nonpara-
metric statistics. Two groups were compared using the nonparametric
Mann–WhitneyU test; multiple groups of data were compared using the
nonparametric Kruskal–Wallis test. The null hypothesis was rejected
when the p level was under 0.05, and, in such cases, the differences were
considered significant throughout this paper.
Results
nNOS is associated with the postsynaptic density of
GABAergic synapses on somata, dendrites, and axon initial
segments of pyramidal cells
In previous studies in the hippocampal CA1 region, the NO syn-
thesizing enzyme nNOSwas found postsynaptically in pyramidal
cells in their excitatory synapses (Wendland et al., 1994; Burette
et al., 2002; Blackshaw et al., 2003). However, by using a preem-
bedding immunogold technique on mildly fixed brains, here we
show for the first time that nNOS can be found not only in den-
dritic spines in mice and rats, but it is also localized to symmet-
rical GABAergic synapses on pyramidal cells. We found no label-
ing in nNOS KO mice (Fig. 1A), whereas, for example, somatic
synapses were strongly labeled in wild-type mice (Fig. 1B,C) in
the very same experiments. In addition, the labeling is not ran-
domly associated with the pyramidal cell membrane, but it is
specifically enriched in symmetrical synapses (Figs. 1B,C,
2A,D–H) as well as in asymmetrical synapses on spines (Fig.
2B,C,N,O). Our measurements of the relative linear density of
labeling show that, whereas labeling density was 1.35  0.31
gold particles per micrometer membrane (mean  SD) in the
synaptic active zone of somatic symmetrical synapses, it was only
0.03 0.02 gold particles per micrometer at extrasynaptic mem-
brane domains in the vicinity of these synapses. Some labeling
also occurs in the cytoplasm of pyramidal cells around cisternae
of the endoplasmic reticulum, and strong labeling is detectable in
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the somata and dendrites of nNOS-
positive interneurons (Fig. 2 I, dendrite d).
Two types of interneurons innervate
the somata of pyramidal cells: those im-
munoreactive for PV establish approxi-
mately two-thirds of terminals on pyrami-
dal cell somata, whereas CCK-positive
interneurons comprise approximately
one-third of somatic terminals (Nyiri et
al., 2001). In mice, we tested fully recon-
structed symmetrical synapses, and we
found that at least76% of these fully re-
constructed somatic synapses (median of
the individual percentages of 16 of 19, 15
of 20, and 16 of 21 in three mice) (Figs.
1B,C, 2A) and at least 32% of the AIS
synapses (median percentage of 7 of 22, 10
of 26, and 6 of 20 in three mice) (Fig.
2E,F) were identified as nNOSpositive on
the basis of immunogold particles associ-
ated with the postsynaptic density. Sup-
posedly, these data underestimate the
number of nNOS-labeled synapses, be-
cause high concentrations of scaffolding
and other proteins in the postsynaptic
density make detection of its constituting
proteins difficult. Because perisomatic GABAergic inhibition is
brought about by three types of interneurons (CCK- and PV-
positive basket cells and PV-positive axo-axonic cells), these data
have strong predictive values. However, dendrite targeting inter-
neurons aremuchmore diverse; therefore, quantification of such
synapses was not performed at the electron microscopic level.
Nevertheless, many of the dendritic symmetrical synapses were
also intensely positive in all three mice investigated. Similar to
mice, somatic (Fig. 2G,I–K), dendritic (Fig. 2H,L), and AIS (Fig.
2M) synapses are labeled in rats aswell. In rats, we also performed
a direct colocalization of nNOS in reconstructed synapses of both
PV- andCCK-positive terminals.We found (in all three rats) that
nNOS labeling was present in postsynaptic active zone of syn-
apses established by CCK-positive and PV-positive terminals on
somata (Fig. 2 I–K), in synapses established by PV-positive ter-
minals on AISs (Fig. 2M), as well as in synapses established by
both CCK-positive and -negative terminals on pyramidal cell
dendrites (Fig. 2L). Because different interneurons target differ-
ent pyramidal cell surface domains, this means that at least five
different types of interneurons establish synapses on pyramidal
cells with postsynaptically located nNOS. The distribution of the
NO receptors provides additional support to this conclusion (see
below).
Cell type-specific expression of the mRNA of NOsGC 1 and
2 subunits in the hippocampus
NOsGC is a heterodimeric enzyme composed of two different
subunits:  (1–2) and  (1–2) (Russwurm et al., 2001; Russ-
wurm and Koesling, 2002; Koesling et al., 2004; Krumenacker et
al., 2004). The subunits initially termed 3 and 3 represent the
human orthologs of the1 and1 subunits, respectively (Zabel et
al., 1998). Studies have also demonstrated that, whereas 1, 2,
and 1 subunits are abundant, there is only a negligible amount
of 2 isoform in the brain (Burgunder and Cheung, 1994; Gibb
and Garthwaite, 2001; Ding et al., 2004), and, even if it is ex-
pressed with 1 or 2 subunits, the complex is either not active
(Koesling, 1999) or has very low activity (Gibb et al., 2003). In
fact, knocking out1 subunit results in a lethal phenotype (Friebe
et al., 2007), whereas knocking out only 1 or 2 subunits does
not result in lethal phenotype (Mergia et al., 2006). Therefore,
there are only two kinds of functionally important subunit com-
positions of NOsGC in the hippocampus that detects NO signal:
11 and21 complexes. Because binding of these subunit com-
positions to synaptic scaffolding protein and possible differences
in their regulation may differentially support signaling in neu-
rons, here we tested which neurons express these isoforms of
NOsGC.Using digoxigenin-labeled riboprobes for in situhybrid-
ization (developed with 5-bromo-4-chloro-3-indolyl-phosphate
and nitro blue tetrazolium chloride dissolved in chromogen
buffer solution) in rats (Fig. 3), we found that 1 subunit mRNA
was only present in interneurons (Fig. 3A–D), and these labeled
neuronswere found in all layers of the CA1 area. On the contrary,
2 subunit mRNAwas only present in pyramidal cells of the CA1
area (Fig. 3E,F). We obtained identical results in mice (data not
shown).
The 1 subunit of NOsGC is present in interneurons and their
terminals, but it is not detectable in pyramidal cells
Because themRNA of NOsGC 1 subunit is selectively present in
interneurons, we performed preembedding immunoperoxidase
staining to test whether the axon terminals of interneurons ex-
press the 1 subunit protein. In addition, we also tested whether
its complementary 1 subunit is also expressed in the very same
cells.
Mice and rats showed an identical staining pattern. We found
that many of the hippocampal interneurons showed strong im-
munostaining for the 1 subunit, and these cells could be found
in all layers of the hippocampus from the alveus to the stratum
(str.) lacunosum-moleculare, similar to its mRNA distribution
(Fig. 4A). Occasionally, interneurons with weaker labeling were
also found. In interneurons, staining appeared strongest in so-
mata, proximal dendrites, and axons. In the light microscope,
basket-like axon terminal labeling appeared in the str. pyramidale
around cell bodies in both species (Fig. 4D, mouse, E, rat). Using
Figure1. Electronmicrographs showing nNOS immunogold labeling postsynaptically at symmetrical synapses inmice and the
lack of labeling in KOmouse. Photos frompreembedding immunohistochemical experiments show the lack of nNOS immunogold
labeling of synapses (open arrowheads) established by axon terminals (t) on somata (s) in nNOS KO mice (A). In the same
experiment, but in wild-type (WT) mice, we observed strong labeling of several GABAergic synapses (B, C). The silver-enhanced
immunogold particles (filled arrowheads) are selectively associated with the postsynaptic density of symmetrical GABAergic
synapses on somata (s). Scale bar, 0.5m.
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electron microscopy of immunoperoxidase-stained tissue and
random samples from reconstructed terminals inmice, we found
that at least 79% of the reconstructed somatic terminals (me-
dian percentage of 20 of 23, 18 of 24, and 23 of 29 in three mice)
(Fig. 4F) and at least 42% of the AIS terminals (median per-
centage of 10 of 21, 4 of 21, and 8 of 19 in three mice) (Fig. 4H)
were positive for the 1 subunit of NOsGC, and many of the
terminals establishing dendritic symmetrical synapses were also
strongly positive in all three mice (Fig.
4G). In rats, we also found that many of
the reconstructed synaptic terminals on
somata (Fig. 4 I), dendrites (Fig. 4 J), and
AISs (Fig. 4K) were also positive for the1
subunit. Furthermore, we also tested 1
subunit labeling at the electron micro-
scopic level in the rat and found that, as
expected, many of the GABAergic termi-
nals are also positive for the 1 subunit
(data not shown). This confirms our find-
ing that the 11 subunit composition of
NOsGC is expressed by these GABAergic
terminals, and they are in a position to de-
tect retrograde NO signals from the pyra-
midal cells.
The 1 subunits always heterodimerize
with 1 subunits. To test whether other
interneurons have abundant 1 subunit
containing NOsGC without the 1 sub-
unit, we investigated the colocalization be-
tween1 and1 subunits in rat hippocam-
pal interneurons (Fig. 4B,C). Because
both antibodies were raised in rabbit, we
used the so-called mirror technique (Ko-
saka et al., 1985), in which cells that were
cut in half on the section surfaces can be
examined in adjacent sections, one incu-
bated with 1 and the other with 1 sub-
unit antibody. As expected, 1 subunits
were found in both pyramidal cells (pri-
marily dendrites) (Burette et al., 2002;
Ding et al., 2004) and interneurons (pri-
marily somata and also proximal den-
drites and terminals), whereas the 1 sub-
unit antibody labeled only interneurons.
We found that 1 subunit-positive inter-
neurons were practically always positive
for the1 subunit (in four rats, 27 of 27, 41
of 42, 34 of 37, and 18 of 19), and, also, 1
subunit-positive interneurons were posi-
tive for the 1 subunit (in four rats, 28 of
29, 41 of 43, 39 of 40, and 16 of 17; some
false-negative cells may occur in the sec-
tions because of the soluble nature of the
1-containing NOsGC or because of the
loss of some soma tissue during section-
ing). Besides confirming the specificity of
the 1 subunit antibody, these results also
suggest that, because no 1 subunit-
positive interneurons were detected with-
out the 1 subunits, there are no interneu-
rons that express only 21 subunit
composition, which is in line with our
finding that 2 subunit mRNA expression
was absent in interneurons.
Both perisomatic and dendrite targeting GABAergic neurons
contain the1 subunit of the NOsGC
As we have shown, many interneurons expressed the mRNA of
NOsGC 1 subunit, and many of them contained NOsGC 1
subunit protein together with the 1 subunit, but not all inter-
neurons were positive. Therefore, we performed a quantitative
Figure 2. Electron micrographs from preembedding experiments showing nNOS immunogold labeling postsynaptically at
symmetrical and asymmetrical synapses in mice and rats. Postsynaptic immunogold labeling for nNOS (arrowheads) in mice
(A–F ) and in rats (G–O) are present not only in asymmetrical spine (sp) synapses (B,C,N,O) but also attached to the postsynaptic
density of symmetrical synapses, in theCA1areaof thehippocampus. Labelingof symmetrical synapses confirmed in serial sections could
be observed on somata (A, G, I–K ), dendrites (A, D, H, L), and AISs (typical undercoating of the membrane is indicated with open
arrowheads inE,F,M ). In rats, nNOSwas colocalizedwithCCK (I,L) andPV (J,K,M ) labeling. I, Strong labelingoccurs in thedendrites (d)
of nNOS-positive interneurons aswell. t, Terminal; s, soma; d, dendrite; sp, spine. Scale bar, 0.5m.
Szabadits et al. • NO Signaling in GABAergic Synapses J. Neurosci., July 25, 2007 • 27(30):8101–8111 • 8105
immunofluorescence study to test
whether major interneuron classes, in-
cluding CCK-, PV-, nNOS-, or SOM-
positive perisomatic or dendrite targeting
interneurons, express this NO receptor.
Although direct colocalization data are
not available for all of these markers in the
rat hippocampal CA1 region, indirect ob-
servations suggest that these four markers
label different, primarily nonoverlapping
populations of interneurons (Freund and
Buzsaki, 1996; Jinno and Kosaka, 2000,
2002, 2004, 2006; Freund, 2003; Seress et
al., 2005). The general staining patterns
with these markers were similar to those
reported previously. NOsGC 1 subunit
staining was identical to that found with
immunoperoxidase (DAB) staining (see
above). No labeling could be detected in
the cell nuclei. With immunofluorescent
staining, we found a variable intensity of
immunolabeling signal; however, we have
not observed a correlation between the
signal intensity and the type of interneu-
ron markers. Thin axon-like processes
could be identified in the surrounding
neuropil with immunofluorescent stain-
ing as well (Fig. 5).
After investigating random samples of labeled interneurons in
the CA1 area of the rat dorsal hippocampi (see Materials and
Methods), we found that the median proportions are the follow-
ing (in parentheses are the number of examined cells in the given
colocalization from the three rats and the percentages in the an-
imals, respectively): from all NOsGC 1 subunit-positive cells,
21% (n  1383; 23, 15, and 21%) are CCK positive (Fig. 5A),
40% (n 1527; 38, 41, and 40%) are PV positive (Fig. 5B), 11%
(n  1322; 11, 10, and 20%) are nNOS positive (Fig. 5C), and
7% (n 1599; 4, 7, and 7%) are SOM-positive (Fig. 5F).
Measuring it from the side of the interneuron markers, we
found that the proportion of NOsGC 1-positive cells are68%
(n 432; 68, 45, and 80%) of all CCK-positive cells,74% (n
771; 74, 74, and 90%) of all PV-positive cells,20% (n 756; 18,
20, and 34%) of all nNOS-positive cells, and32% (n 264; 37,
32, and 31%) of all SOM-positive cells.
Although direct and indirect data suggest that these four in-
terneuron markers show only negligible colocalizations, little in-
formation was available about possible colocalization between
nNOS- and CCK-positive cells. Because practically all CCK-
positive cells are CB1 receptor-positive (Katona et al., 1999;Hajos
et al., 2000), we tested whether CB1 receptor labeling and nNOS
labeling can be found in the same cells (Fig. 5E), but we observed
no colocalization between these twomarkers in the random sam-
ples (n 206 CB1-positive cells in three rats).
Vruwink et al. (2001) suggested that there was a reciprocal
chemical interaction between two inhibitory networks in the rat
neocortex. One of them is positive for SPR and nNOS, and the
other is substance P and NOsGC positive. They reported that
there is a 94–95% overlap (in both directions) between nNOS-
positive and SPR-positive cells in the neocortex. Therefore, be-
sides testingNOsGC1-positive cells for nNOS in the hippocam-
pus, we also tested whether there is a strong overlap between
nNOS- and SPR-containing cells in the hippocampus as well.
Here we show that, in the hippocampal CA1 region, this overlap
is far from that observed in the neocortex.We found that, fromall
SPR-positive cells,47% (n 709; 47, 41, and 50%) were nNOS
positive, whereas from all nNOS-positive cells,43% (n 654;
43, 37, and 68%) were SPR positive (Fig. 5D).
Generation of cGMPbyNOsGC appears to be a crucial step in
NO signaling in the brain (Boulton et al., 1994; Ahern et al., 2002;
Monfort et al., 2004;Makhinson et al., 2006). In subcortical areas,
several studies demonstrated that the NO–NOsGC–cGMP path-
way can either facilitate (Klyachko et al., 2001; Kraus and Prast,
2002; Li et al., 2004) or inhibit (Ozaki et al., 2000) GABAergic
neurotransmission. There are at least threemolecular targets that
can mediate the action of cGMP in the brain. These are (1) the
cyclic nucleotide gated ion channels (Zagotta and Siegelbaum,
1996), some of which have already been detected in hippocampal
interneurons (Kingston et al., 1996; Maccaferri and McBain,
1996; Lorincz et al., 2002), (2) cGMP-dependent phosphodies-
terases, some of which have also been shown to be expressed in
these interneurons (Van Staveren et al., 2002, 2003; Domek-
Lopacinska, 2005) and (3) the cGMP-dependent protein kinase
(PKG), which may also be present in these interneurons (Klep-
pisch et al., 1999; Feil et al., 2005; de Vente et al., 2001, their Fig.
4b). The type II PKG is widely expressed on axon terminals and
dendrites in the brain (de Vente et al., 2001), and it was also
suggested that the NO-induced increase in synaptic GABA re-
lease to spinally projecting paraventricular nucleus neurons is
through PKG activation targeted by cGMP (Li et al., 2004).
Therefore, because these targetmolecules are likely present in the
terminals of hippocampal interneurons, NO signal may have a
strong potential and several pathways to modulate GABAergic
transmission onto pyramidal cells.
Correlation between the soma size of certain interneuron
types and NOsGC1 subunit content
In many cases, the function and/or the metabolic state of a neu-
ron can correlate with the size of its cell body; therefore, we tested
whether the sizes of different interneurons correlate with their
Figure 3. mRNA expression of NOsGC1 and2 subunits in the hippocampal CA1 region. Lightmicrographs show a nonover-
lappingmRNA labeling of the two subunits. Labeling sectionswith the sense probes for NOsGC1 (A) or2 (F ) subunits provided
no specific signal. Only interneurons are stained for NOsGC 1 subunit in the str. radiatum (B), str. pyramidale (C), and oriens/
alveus (D) region. On the contrary, labeling for the2 subunit is present only in pyramidal cells (E). We found identical labeling
pattern in mice (data not shown). r, Str. radiatum; p, str. pyramidale; o, str. oriens. Scale bar, 50m.
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NOsGC 1 subunit content. We measured the cross-sectional
area of the labeled interneurons in a given color and distributed
these data into two groups according to the1 subunit content of
the cells for comparison. In the case of CCK- and SOM-positive
cells, there was no correlation between NOsGC 1 subunit con-
tent and the size of the somata. Interestingly, however, we found
that the cross-sectional areas of PV-
positive somata containing NOsGC 1
subunit labeling were significantly larger
than those that were negative for the sub-
unit. On average, they were 164.75 and
136.44 m2, respectively, which means
that their area was 21% larger ( p 
0.001). (If one calculates with hypotheti-
cally spherical cells, their volume is33%
larger.) In the case of nNOS-positive in-
terneurons, the cross-sectional areas of so-
mata containing NOsGC 1 subunit la-
beling were significantly smaller than
those that were negative for the subunit.
On average, they were 121.13 and 131.81
m2, respectively, which means that their
area was 8% smaller ( p  0.01). (If,
again, one calculates with hypothetically
spherical cells, the difference is 12% in
volume.)
Discussion
The major findings of the present study
are that (1) in hippocampal pyramidal
cells, nNOS is associated with the postsyn-
aptic active zone of different GABAergic
synapses, (2) NOsGC is localized in the
soma-dendritic compartment as well as
axon terminals of interneurons, and (3)
NOsGC 11 is selectively localized in in-
terneurons, whereas principal cells express
the 21 subunit composition. These data
suggest that NO can directly modify
GABAergic synapses on hippocampal py-
ramidal cells in an activity-dependent
manner in both mice and rats.
Synapse-specific NO production in
GABAergic synapses
Hippocampal pyramidal cells are known
to express nNOS (Wendland et al., 1994;
Blackshaw et al., 2003), and its precise lo-
calization to the postsynaptic density of
excitatory synapses was also described
(Burette et al., 2002). The probable reason
for the lack of data about its occurrence in
GABAergic synapses is that its role in long-
term plasticity of excitatory synapses
gained more attention (see Introduction)
and also because the nNOS signal can be
detected only after a very mild fixation in
preembedding experiments (see Materials
and Methods).
Pyramidal cells of the hippocampal
CA1 area are regulated by different types
of interneurons (Freund and Buzsaki,
1996), which target distinct domains of
pyramidal cells. Our quantitative results
and colocalization experiments suggest that most of the synapses
of both kinds of basket cells (PV-andCCK-containing) are nNOS
positive in mice and rats. Similarly, AIS synapses established by
axo-axonic cells and many of the dendritic synapses were also
nNOS positive.
Figure4. Light and electronmicrographs frompreembedding immunoperoxidase labeling for NOsGC inmice and rats.A, Light
micrograph shows the general pattern of labeling for the NOsGC1 subunit in the different layers of the hippocampus (o., oriens;
p., str. pyramidale; r., str. radiatum; l-m., str. lacunosum-moleculare). B, C, Photos from the “mirror experiments” showing that
interneurons (arrowheads) that are cut on the surface of the sections are positive for both1 (in B) and1 (in C) subunit of the
NOsGC. White arrowheads show1 subunit labeling in pyramidal cell dendrites very close to the section surface. D, E, A higher-
magnification light micrograph of the pyramidal cell layer shows NOsGC1 subunit labeling in basket cell-like terminals (arrow-
heads), in both mice (D) and rats (E). Asterisks indicate pyramidal cell somata. F–K, Electron micrographs of1 subunit-labeled
terminals establishing synapses on somata (s; F, I ), dendrites (d;G, J ), and axon initial segments (a;H,K; white arrowheads show
undercoating that is typical for AIS) inmice (F–H ) and rats (I–K ). Scale bars: A, 50m;B, C, 25m;D, E, 10m; F–K, 250 nm.
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NO can freely cross membranes, but
the NO signal remains detectable only in a
fewmicrometers around its site of produc-
tion (Namiki et al., 2005; Iino, 2006).
High-affinity binding of NO to NOsGC
can lead to 200-fold activation of the en-
zyme (Koesling et al., 2004), and deactiva-
tion is also unexpectedly fast (Bellamy et
al., 2000; Bellamy and Garthwaite, 2001).
These properties suggest thatNO signaling
is not only fast reacting and effective but
also synapse specific. Our results show that
nNOS is highly enriched within GABAer-
gic synapses (in the postsynaptic mem-
brane) comparedwith adjacent nonsynap-
tic membrane domains, and interneuron
terminals forming these synapses contain
the NO receptor NOsGC. This spatially
specific arrangement of molecules sug-
gests that there is a synapse-specific retro-
grade signaling in these synapses, similar
to what physiological data suggested in the
ventral tegmental area (Nugent et al.,
2007).
nNOS is activated by calcium–calmod-
ulin under conditions of elevated intracel-
lular calcium concentrations in the pres-
ence of arginine (Bredt and Snyder, 1992;
Prast and Philippu, 2001). In excitatory
synapses, the increase in local calcium
concentration is maintained by synaptic
NMDA receptors and other voltage-gated
calcium channels. However, it is less clear
which processes lead to sufficiently ele-
vated calcium levels around GABAergic
synapses postsynaptically. L- and T-type
calcium channels are present around these
synapses in the dendritic and perisomatic
membranes (Magee et al., 1998; Kali and
Freund, 2005). These channels may be ac-
tivated by both dendritic and back-
propagating action potentials that can lead
to an increased calcium concentration,
providing temporal specificity to this
synapse-specific modulation. Muscarinic
(especially M1) receptor activation, elevat-
ing local calcium concentrations, may also
trigger the nNOS–NO–NOsGC–cGMP
pathway, as it was shown in several para-
digms (Castoldi et al., 1993; Hu and el-
Fakahany, 1993; Ando et al., 1994; Mathes
and Thompson, 1996; Liu et al., 1997;
Borda et al., 2005; Cuadra and El-
Fakahany, 2005). In addition,muscarinic enhancement of R-type
calcium currents has also been observed in hippocampal pyrami-
dal neurons (Tai et al., 2006), whereas M1 receptors are widely
expressed in pyramidal cells (Levey et al., 1995, 1996). In vivo, M1
receptors can be activated by the septohippocampal cholinergic
pathway that plays a crucial role in synaptic plasticity (Freund
andBuzsaki, 1996). Together, these data suggest that amachinery
that can trigger nNOS activity is present around GABAergic syn-
apses, and it could be activated in a precisely timed manner via
action potential-induced calcium influx that may need to coin-
cide with muscarinic receptor-mediated elevation of the local
calcium concentration.
Cell type-specific expression of NOsGC subunits and its
association with nNOS
Expression of the NOsGC subunit mRNA has been reported pre-
viously in 8-d-old rat hippocampus at low magnification, show-
ing a weak 1 and a stronger 2 and 1 subunit expression (Gibb
and Garthwaite, 2001). In adult rats, a large difference appears to
be maintained between the 1 and 2 subunit expression at low
Figure 5. Fluorescent colocalization of NOsGC 1 subunit and different interneuron markers in the rat hippocampal CA1
region. Fluorescent lightmicrographs show a partly overlapping labeling of NOsGC1 subunit with several types of interneurons
that are CCK (A), PV (B), nNOS (C), or SOM (F ) positive.D, nNOS and SPR show a partly overlapping labeling as well; however, CB1
and nNOS positivity could not be detected in the same cells (E). Arrowheads show cells with colocalized markers, and open
arrowheads show cells labeled only with one of the markers. Scale bar, 50m.
8108 • J. Neurosci., July 25, 2007 • 27(30):8101–8111 Szabadits et al. • NO Signaling in GABAergic Synapses
magnification (Pifarre et al., 2007, their Fig. 4A–C). Our results
are the first to reveal the high-resolution localization of the 
subunits at the cellular level in the hippocampus, along with an
immunohistochemical demonstration of the segregation of the
1 and 2 subunit labeling. These findings revealed that, whereas
the 11 subunit composition of NOsGC is expressed only in
interneurons, 21 complexes are restricted to pyramidal cells in
both mice and rats. Our results that practically all 1 subunit-
positive interneurons were positive for 1 subunit and vice versa
not only confirm the specificity of the antibodies but also provide
immunohistochemical evidence that there are no interneurons
expressing only 2 subunit-containing NOsGC.
Most perisomatic axon terminals express NOsGC 1 subunit,
which makes it highly probable that both kinds of somatic inhib-
itory synapses are labeled in these animals. In addition, many of
the axo-axonic terminals also expressed NOsGC. These data
match well with those observed for nNOS labeling in perisomatic
synapses, which suggest that, at any given time, expression of NO
synthase and NO receptors on the two sides of the synapses do
coincide. NOsGC labeling of dendritic and perisomatic GABAer-
gic terminals in mice and rats confirmed that the NO signal can
be detected in these terminals.
Although the primary structure of the two  subunits differ
considerably in the regulatory domain, so far, the two isoforms
11 and 21 do not seem to show any functionally relevant
differences in their regulatory properties, substrate affinity, cata-
lytic rates, or NO sensitivity (Russwurm et al., 1998). However, a
selective subcellular targeting can be mediated by the two differ-
ent  subunits. Recent results show that, whereas the 11 iso-
form is cytosolic, the 21 isoform is associated with the PDZ-
domain-containing PSD-95 (Russwurm et al., 2001). In fact,
recent data suggest that PSD-95 can interact with almost all
members of the NO/cGMP signaling cascade, including nNOS
(Brenman et al., 1996; Russwurm andKoesling, 2002; Koesling et
al., 2004). Therefore, we suggest that, in the excitatory synapses of
hippocampal pyramidal cells, PSD-95 binds NOsGC 21 to-
gether with nNOS and NMDA receptors postsynaptically (Russ-
wurm and Koesling, 2002; Koesling et al., 2004), whereas presyn-
aptically 21 can bind to other PDZ-domain-containing
scaffolding proteins such as synapse-associated protein 97 (Mul-
ler et al., 1995). Conversely, at the GABAergic synapses terminat-
ing on pyramidal cells, PSD-95 was not yet observed, but a seven
PDZ-domain-containing glutamate receptor interacting protein
1 (GRIP1) was demonstrated postsynaptically (Charych et al.,
2004; Kittler et al., 2004). Therefore, GRIP1 could be a docking
site for the nNOS molecules at GABAergic synapses, in which
NOsGC 21 isoform may also be anchored. However, as we
found here, the11 isoform is present on the presynaptic side of
these synapses, i.e., within the GABAergic boutons. One could
also speculate that, because excitatory synapses terminating on
interneurons also express PSD-95 (El-Husseini et al., 2000), ab-
sence of the 2 subunit from interneurons might ensure that
these interneurons do not target NOsGC to their afferent excita-
tory inputs, thereby preventing a form of synaptic plasticity.
nNOS- and NOsGC-mediated signaling is not equally
available to all GABAergic synapses
In situ hybridization and preembedding immunohistochemical
data suggested that not all interneurons are uniformly positive for
NOsGC 1 subunit. By investigating four rarely overlapping in-
terneuron populations, our fluorescent data showed that,
whereas the majority of the perisomatic CCK- and PV-positive
interneurons do express NOsGC, only less than one-third of the
dendrite-targeting SOM- or nNOS-positive interneurons are
NOsGC positive. We also show here that CCK-positive basket
cells that we identified by immunostaining for CB1 receptors
never overlapped with the nNOS-containing population in the
CA1 area. These data combined with our electron microscopic
analysis suggest that NOsGC-positive interneurons belong to at
least five different interneuron populations, because terminal la-
beling was shown for at least two kinds of PV-positive interneu-
rons, in addition to the CCK, SOM, and nNOS cells. Localization
of NOsGC in only a subset of these interneurons does not neces-
sarily mean that NOsGC content would further subdivide these
interneuron types into new subgroups. Instead, it can be a dy-
namically changing, state-dependent feature of these cells. None-
theless, it is interesting that a significant correlation exists be-
tween the size of the PV- or nNOS-positive somata and their
NOsGC 1 subunit content, which predicts that the presence of
NOsGC is related to a substantial metabolic difference, even
within the same interneuron population (whether causally, re-
mains to be established).
Together, our results revealed that the molecular machinery
for NO signaling is present in the majority of hippocampal
GABAergic synapses, and it is different from that found in gluta-
matergic synapses. This molecular difference may allow a selec-
tive and differential manipulation of inhibitory and excitatory
synaptic plasticity, which carries promise for future pharmaco-
therapy of disorders associated with an imbalance of inhibition
and excitation in the cerebral cortex.
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